Growth hormone replacement throughout life: Insights into age-related responses to treatment

Clayton, Peter E.; Gleeson, Helena; Monson, John P.; Popović, Vera; Shalet, Stephen M; Christiansen, Jens Sandahl

doi:10.1016/j.ghir.2007.04.010

Cited by 49 publications

(43 citation statements)

References 96 publications

(164 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thirteen out of those 75 panhypopituitary patients (17.3%) also had diabetes insipidus. This is also similar to what has been reported in the literature for other GHD populations (36)(37)(38).…”

Section: Duration Of Ghd (Years)supporting

confidence: 92%

“…The validation survey involved 120 patients from multiple centers who were representative of the Brazilian GHD population. These patients were similar to those enrolled for validation of the QoL-AGHDA in other countries (35,(37)(38)(39). Sixty-seven point five percent (67.5%) of the sample completed the QoL-AGHDA at both administrations.…”

Section: Convergent Validitymentioning

confidence: 66%

“…Mean ( surgery and morbidity (34,35). Twenty-six (32.9%) of these patients had also undergone radiotherapy.…”

Section: Duration Of Ghd (Years)mentioning

confidence: 99%

See 2 more Smart Citations

The brazilian version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): Four-stage translation and validation

Ribeiro‐Oliveira

Mol

Twiss

et al. 2010

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Objective: This study reports on the Brazilian Portuguese adaptation of the QoL-AGHDA (Quality of Life Assessment of Growth Hormone Deficiency in Adults) for use in adult growth hormone deficient (GHD) patients. Materials and methods: The translation process adopted the dual panel methodology. The questionnaire was tested through field-test interviews (16 GHD patients). In the final stage, data from 120 GHD patients (81 included in a test-retest analysis) were analyzed for internal consistency, test-retest reliability, convergent validity and validity among known groups. Results: The translation panels were successful and the draft version was amended to improve the wording as a result of the field-test interviews. Cronbach's alpha was 0.90 and test-retest reliability 0.88. QoL-AGHDA scores had the expected pattern of association with NHP scale scores and QoL-AGHDA was able to differentiate significantly between patients based on patient-reported general health (p < 0.01) and QoL (p < 0.01). Conclusions: The adaptation of the QoL-AGHDA for a Brazilian population was successful and the adapted questionnaire was shown to be reliable and valid. Arq Bras Endocrinol Metab. 2010;54(9):833-41 Keywords Growth hormone; quality of life; treatment outcomes; QoL-AGHDA RESUMO Objetivo: Este estudo relata o processo de adaptação da versão brasileira do questionário QoL--AGHDA (Quality of Life -Assessment of Growth Hormone Deficiency in Adults) para pacientes com deficiência do hormônio de crescimento (DGH). Materiais e métodos: A tradução adotou a metodologia de duplo painel. O questionário foi testado por intermédio de entrevistas direcionadas com 16 pacientes com DGH. No estágio final, dados de 120 pacientes com DGH (81 com teste/reteste) foram analisados para consistência interna, confiabilidade teste/reteste, validade convergente e validade entre grupos conhecidos. Resultados: Os grupos de tradução foram bem-sucedidos e a versão final foi adaptada seguindo sugestões obtidas das entrevistas com os 16 pacientes. O coeficiente alfa de Cronbach foi 0,90, confiabilidade teste/reteste 0,88, escores QoL-AGHDA se correlacionaram com o NHP (p < 0,01) e também com a saúde geral relatada pelos pacientes (p < 0,01). Conclusões: A adaptação do QoL-AGHDA para a população brasileira foi bem-sucedida, e a nova versão demonstrou ser válida e confiável. Arq Bras Endocrinol Metab. 2010;54(9):833-41 Descritores Hormônio do crescimento; qualidade de vida; terapêutica; QoL-AGHDA

show abstract

Section: Duration Of Ghd (Years)supporting

confidence: 92%

Section: Convergent Validitymentioning

confidence: 66%

See 1 more Smart Citation

The brazilian version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): Four-stage translation and validation

Ribeiro‐Oliveira

Mol

Twiss

et al. 2010

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Middle-aged (31-60 years) Elderly (R61 years) Difference with GH deficiency (9)(10)(11), it is difficult to explain the finding of higher IGF1 SDS in the elderly acromegalic patients. In the present study, the age differences in the higher IGF1 SDS were remarkable in female patients and the sex differences in IGF1 and IGF1 SDS were found in young and middle-aged patients but not in elderly patients.…”

Section: Young (%30 Years)mentioning

confidence: 99%

The influence of age on the GH–IGF1 axis in patients with acromegaly

Tanimoto

Hizuka

Izumi³

et al. 2008

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: The purpose of this study was to investigate the influence of age on GH and IGF1 axis, and complications in patients with acromegaly. Subjects and methods: From the medical records, we retrospectively analyzed clinical features and complications in 87 newly diagnosed patients with active acromegaly (34 males, 53 females; aged 18-82 years) who were admitted to Tokyo Women's Medical University between 1999 and 2006. We divided the patients into three groups according to age: %30 years old (young group), 31-60 years old (middle-aged group), and R61 years old (elderly group). Results: The median GH levels in young, middle-aged, and elderly groups were 18.5, 8.8, and 6.7 mg/l respectively, and the IGF1 levels were 810, 717, and 740 mg/l respectively. The values were not significantly different among the groups. However, the serum IGF1 SDS were significantly higher in the elderly group (10.2) than those in young and middle-aged groups (6.6 and 6.2 respectively, P!0.001). The age difference in the higher IGF1 SDS was remarkable in female patients. In the elderly group, glucose intolerance and hypertension were found in 94 and 53% of the patients respectively and the incidences were higher than those in the other groups. Conclusion: This study suggests that the relatively high IGF1 secretions in elderly patients might be involved in the progression of clinical complications in acromegalic patients. Therefore, awareness of the early symptoms and examination of serum GH and IGF1 are important for patients with acromegaly.

show abstract

“…GH replacement therapy is approved for adults with severe GHD based on its favorable impact in metabolic indices, cardiovascular risk factors, body composition, and quality of life (1-3). As a consequence, it is now recognized that some patients with childhood-onset GHD (CO-GHD) may need to continue GH replacement during adulthood to achieve full somatic development and to avoid GHD-associated morbidities (4,5).…”

Section: Introductionmentioning

confidence: 99%

Reappraisal of serum insulin-like growth factor-I (IGF-1) measurement in the detection of isolated and combined growth hormone deficiency (GHD) during the transition period

Boguszewski

Lacerda

Filho

et al. 2013

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

OBJECTIVE: To evaluate the accuracy of serum IGF-1 in the detection of isolated (IGHD) or combined growth hormone deficiency (CGHD) at the transition phase. SUBJECTS AND METHODS: Forty nine patients with GHD during childhood [16 with IGHD (10 men) and 33 with CGHD (24 men); age 23.2 ± 3.5 yrs.] were submitted to an insulin tolerance test (ITT) with a GH peak < 5 µg/L used for the diagnosis of GHD at the transition phase. Pituitary function and IGF-1 measurements were evaluated in the basal sample of the ITT. Transition patients were reclassified as GH-sufficient (SGH; n = 12), IGHD (n = 7), or CGHD (n = 30). RESULTS: Five (31%) patients with IGHD and 32 (97%) with CGHD at childhood persisted with GHD at retesting. One patient with IGHD was reclassified as CGHD, whereas 3 patients with CGHD were reclassified as IGHD. Mean GH peak was 0.2 ± 0.3 µg/L in the CGHD, 1.3 ± 1.5 µg/L in the IGHD, and 18.1 ± 13.1 µg/L in the SGH group. Serum IGF-1 level was significantly higher in the SGH (272 ± 107 ng/mL) compared to IGHD (100.2 ± 110) and CGHD (48.7 ± 32.8) (p < 0.01). All patients reclassified as CGHD, 86% reclassified as IGHD, and 8.3% reclassified as SGH had low IGF-1 level, resulting in 97.3% sensitivity and 91.6% specificity in the detection of GHD at the transition period; the cutoff value of 110 ng/mL showed 94.5% sensitivity and 100% specificity. Mean IGF-1 values did not differ in IGHD or CGHD associated with one, two, three, or four additional pituitary deficiencies. CONCLUSION: IGF-1 measurement is accurate to replace ITT as initial diagnostic test for IGHD and CGHD detection at the transition phase.

show abstract

Growth hormone replacement throughout life: Insights into age-related responses to treatment

Cited by 49 publications

References 96 publications

The brazilian version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): Four-stage translation and validation

The brazilian version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): Four-stage translation and validation

The influence of age on the GH–IGF1 axis in patients with acromegaly

Reappraisal of serum insulin-like growth factor-I (IGF-1) measurement in the detection of isolated and combined growth hormone deficiency (GHD) during the transition period

Contact Info

Product

Resources

About